Novartis this week became the fifth manufacturer to sue the Health Resources and Services Administration (HRSA) to implement a 340B [...] …
Category: Regulatory
Yesterday’s New York Times investigative article alleging that the 340B prime vendor, Apexus, profited by driving 340B program expansion has [...] …
The Health Resources and Services Administration (HRSA) has terminated the 340B status of 20 sites affiliated with the Nevada-based STD [...] …
Four drugmakers have notified 340B covered entities of changes to certain national drug codes (NDC) for their products over the [...] …
Three large drugmakers are suing the federal government for allegedly allowing certain STD clinics to unlawfully participate in the 340B [...] …
A major hospital advocacy group recently warned that October 2024 agency guidance on Medicare drug price negotiations may allow drugmakers [...] …
Emerging regulatory conflicts between the Inflation Reduction Act (IRA) and the 340B program may soon force policymakers to enact major [...] …
French pharmaceutical giant Sanofi late yesterday announced it would pause the implementation of its contested 340B rebate plan and become [...] …
Breaking News
HRSA Threatens to Remove Sanofi from 340B Program Over ‘Unapproved’ 340B Rebate Proposal
The federal department that oversees the 340B program told Sanofi late Friday afternoon that it must cease implementation of its [...] …
The West Virginia Board of Pharmacy is beginning to act on its growing backlog of alleged violations to the state’s [...] …